問卷

TPIDB > Principal Investigator

Principal Investigator


Hsinchu Mackay Memorial Hospital (在職)

Division of Dermatology

MacKay Memorial Hospital (在職)

Division of Dermatology

MacKay Memorial Hospital

Division of Dermatology

更新時間:2023-09-19

吳南霖
  • Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

33Cases

2025-11-01 - 2030-06-07

Others

Active
A phase 3b/4, multicenter, randomized, open-label, long-term safety trial comparing deucravacitinib with ustekinumab in participants with moderate to severe plaque psoriasis (PRAGMATYK).
  • Condition/Disease

    Participants with moderate to severe plaque psoriasis (PRAGMATYK)

  • Test Drug

    Shu Ting Coated Tablets 6 mg

Participate Sites
7Sites

Not yet recruiting5Sites

Recruiting2Sites

2025-11-03 - 2027-12-31

Phase III

Active
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of OBI- 858 in Subjects with Moderate to Severe Glabellar Lines.
  • Condition/Disease

    Moderate to severe frown lines

  • Test Drug

    Freeze-dried injection

Participate Sites
8Sites

Recruiting8Sites

2025-10-01 - 2028-04-30

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2020-10-09 - 2020-12-10

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2018-10-01 - 2020-02-28

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2020-06-01 - 2021-06-16

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2024-01-01 - 2027-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2023-11-01 - 2027-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting5Sites

Recruiting1Sites

2024-09-01 - 2031-08-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2023-02-01 - 2024-08-08

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

1 2 3 4